Company Overview
Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for the detection of MRD; and NeXT Dx, a tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. In addition, the company performs whole exome sequencing of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing on human samples for research projects, such as population sequencing initiatives. Its services are used by pharmaceutical companies for translational research, biomarker discovery, the development of personalized cancer therapies, and for clinical trials, as well as tests are used by physicians to detect residual or recurrent cancer in patients, monitor cancer response to therapy, and uncover insights for therapy selection. The company's customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and cancer patients. The company has strategic collaboration with Tempus AI, Inc. to bring testing to colorectal cancer patients. Personalis, Inc. was incorporated in 2011 and is headquartered in Fremont, California.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.15.
Recent Developments
- Dec 2025 Revenue of $69.65M (-17.7% YoY); net profit $-81.27M.
- Trailing 12 Months Year-on-year growth — revenue -24.9%.
- 5-Year Trend Long-term compounding — revenue CAGR 2.3%, profit CAGR 9.4%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 2.30% |
| 1 Year: | -24.90% |
Compounded Profit Growth
| 5 Years: | 9.43% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +132.30% |
| 6 Months: | +85.56% |
| 3 Months: | +138.19% |
| 1 Month: | +59.55% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)71.78 · Overbought
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | PSNL Personalis, Inc. R2K | 15.03 | -14.74 | $1.57B | 0.00% | -27.52% | -41.35% | 2.30% | 9.43% |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.16M | 8.80M | 11.65M | 13.16M | 14.07M | 15.82M | 17.15M | 18.15M | 19.16M | 19.50M | 19.82M | 20.88M | 21.67M | 22.26M | 15.23M | 18.24M | 14.86M | 18.86M | 16.70M | 18.25M | 19.52M | 22.58M | - | - | 20.61M | 17.20M | 14.49M | 17.34M | 15.47M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 13.40M | 12.45M | 12.58M | 15.45M | 15.19M |
| Gross Profit | 99.00K | 2.40M | 4.48M | 4.83M | 3.98M | 5.90M | 5.63M | 6.57M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 7.21M | 4.76M | 1.91M | 1.90M | 281.00K |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 24.90M | 26.56M | 25.20M | 27.17M | 32.44M |
| Operating Income | - | -3.71M | -1.75M | - | -5.43M | -4.06M | -5.73M | - | -9.62M | -9.50M | -9.65M | -12.49M | -14.95M | -17.69M | -28.31M | -27.88M | -27.26M | -29.82M | -25.35M | -30.79M | -18.88M | -16.89M | - | - | -17.70M | -21.80M | -23.29M | -25.27M | -32.16M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -13.13M | -17.48M | -19.12M | -21.28M | -27.60M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 28.00K | 48.00K | 64.00K | 65.00K | 47.00K |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -15.74M | -20.05M | -21.65M | -23.80M | -30.02M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 7.00K | 2.00K | 3.00K | 9.00K | 16.00K |
| Net Income | -5.38M | -7.32M | -3.64M | -3.56M | -5.68M | -5.87M | -6.88M | -6.64M | -9.14M | -9.26M | -9.54M | -12.40M | -14.95M | -17.67M | -28.21M | -27.55M | -26.49M | -28.66M | -23.95M | -29.10M | -12.97M | -12.80M | - | - | -15.75M | -20.06M | -21.65M | -23.81M | -30.03M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | -0.34 | -0.40 | -0.63 | -0.60 | -0.58 | -0.61 | -0.50 | -0.60 | -0.26 | -0.24 | - | - | -0.18 | -0.23 | -0.24 | -0.26 | -0.29 |
| R&D Expense | - | 3.50M | 3.57M | - | 5.25M | 4.50M | 5.30M | - | 6.39M | 6.46M | 7.19M | 9.50M | 11.69M | 13.62M | 17.10M | 16.29M | 14.96M | 16.57M | 17.85M | 16.74M | 12.77M | 12.96M | 11.68M | - | 12.64M | 12.38M | 12.17M | - | 14.54M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 9.39M | 37.77M | 65.21M | 78.65M | - | 65.05M | 73.48M | 84.61M | 69.65M |
| Cost of Revenue | - | - | - | - | - | 51.70M | 55.27M | 57.79M | 53.87M |
| Gross Profit | - | - | - | - | - | 13.35M | 18.21M | 26.82M | 15.78M |
| Operating Expenses | - | - | - | - | - | 128.88M | 114.50M | 95.09M | 103.83M |
| Operating Income | -22.16M | -13.77M | -22.42M | -42.15M | - | -115.53M | -96.29M | -68.27M | -88.06M |
| EBITDA | - | - | - | - | - | -104.64M | -96.81M | -70.30M | -71.00M |
| Interest Expense | - | - | - | - | - | 201.00K | 110.00K | 24.00K | 205.00K |
| Pretax Income | - | - | - | - | - | -113.28M | -108.21M | -81.27M | -81.25M |
| Tax Provision | - | - | - | - | - | 40.00K | 83.00K | 18.00K | 21.00K |
| Net Income | -23.60M | -19.89M | -25.08M | -41.28M | - | -113.31M | -108.30M | -81.28M | -81.27M |
| Diluted EPS | - | - | - | -1.20 | - | -2.48 | -2.25 | -1.37 | -0.91 |
| R&D Expense | 9.92M | 14.30M | 22.42M | 28.57M | 49.31M | 64.91M | 64.78M | 48.91M | 50.26M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 41.67M | 157.29M | 244.84M | - | 292.70M | 225.10M | 270.27M | 334.16M |
| Current Assets | - | - | - | - | - | - | 199.70M | 146.74M | 203.01M | 267.95M |
| Cash & Equivalents | - | - | 19.74M | 55.05M | 68.53M | - | 89.13M | 56.98M | 91.42M | 124.25M |
| Inventory | - | - | - | - | - | - | 6.38M | 5.66M | 3.98M | 5.26M |
| Receivables | - | - | - | - | - | - | 16.64M | 17.73M | 8.14M | 16.20M |
| Total Liabilities | - | - | 58.65M | 50.60M | 49.90M | - | 74.56M | 95.66M | 67.31M | 72.98M |
| Current Liabilities | - | - | 57.85M | 49.96M | 40.64M | - | 33.13M | 47.23M | 31.13M | 39.63M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | - | 48.65M | 47.73M | 44.25M | 39.95M |
| Total Equity | -69.84M | -92.60M | -106.39M | 106.69M | 194.94M | - | 218.14M | 129.44M | 202.96M | 261.19M |
| Shares Outstanding | - | - | - | - | - | - | 46.71M | 50.48M | 85.17M | 102.48M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 290.00K | 5.57M | -18.07M | -42.65M | -70.83M | -70.23M | -56.26M | -45.15M | -74.95M |
| Investing Cash Flow | -5.16M | -7.85M | -81.58M | -65.14M | -60.07M | 52.54M | 13.10M | -35.07M | -22.57M |
| Financing Cash Flow | 16.40M | -591.00K | 134.95M | 121.27M | 169.70M | 1.37M | 11.03M | 114.67M | 130.34M |
| Capital Expenditure | -5.16M | -7.85M | -8.38M | -3.25M | -11.08M | -49.90M | -10.91M | -1.60M | -4.50M |
| Free Cash Flow | -4.87M | -2.28M | -26.45M | -45.90M | -81.91M | -120.13M | -67.17M | -46.75M | -79.45M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | 20.5% | 24.8% | 31.7% | 22.7% |
| Operating Margin % | -236.0% | -36.5% | -34.4% | -53.6% | - | -177.6% | -131.0% | -80.7% | -126.4% |
| Net Margin % | -251.2% | -52.6% | -38.5% | -52.5% | - | -174.2% | -147.4% | -96.1% | -116.7% |
| ROE % | 25.5% | 18.7% | -23.5% | -21.2% | - | -51.9% | -83.7% | -40.0% | -31.1% |
| ROCE % | - | 85.1% | -20.9% | -20.6% | - | -44.5% | -54.1% | -28.5% | -29.9% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for PSNL
Cancer Test for Small DNA Traces Can Now Be Used in Great Britain - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxPcDZaVlJTbFVKQmF0QU0yemwxb0ljLU80T3o0QVlCMzdVTXdjZzZjWGxSSDVGcnZJSmkyZ2N0UzRQZzhaTXQ0ZW0wOG5oWGJhanU5QmFTekNhR0VfQ2swWEZzLUQwNmJpVFF0dmtUNWVlZ0Via0prTnUzQjNsbnBGVzBFQ2Z0di05cUhMQ0…
$PSNL stock is up 12% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxOT2hBcEV2STBUeUJnclV1cUI3aWJELU1OMTNpNFVSYjYwSk4yb2JaNk5ULTVpelFvWWNqWTUzeVNWemU5V3R6NF9ZaE5iNlltbGdNOTh4X2xucVJibE9DcEI2dmNtX29CT2o4NnZ4Q0dQUjNpd3VpSU9aVkZCRUdhSE9JZldzVUdzcy1ONm…
PSNL Stock Climbs As Morgan Stanley Lifts Price Target - StocksToTrade
<a href="https://news.google.com/rss/articles/CBMidkFVX3lxTE5xZXlwRlFmeVJJQmdkM3dvRlZ4WllXVGo2MWE1Sm5XaXQzbHpVR2ktcFNwTlFzS082S25kdmZxcExPMThHdkNpUnlTWjFYZ2QxNmNCdUtCa1BYMXFMT0g2MkxyNkRINlI1TEpIbWI2aWVDaXhfS1E?oc=5" target="_blank">PSNL Sto…
Personalis (PSNL) Stock Looks Rich Even After A Very Large Run - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi3AFBVV95cUxPdWRoZzB5VllqZ3liT29XbENsVFhlVXRIYUxSUm5HRVRKdUtJbUVZS1dlVVZIVklrMTZka1FpWjBuSG9LSHFncUZLbmRzWnV4VkFsRXN2VFAtLS10bEZuZ0dqSUxLdmxLOXZzNmVzcF85SFVLRGxpb3hlU2JJYklrMjl0NThRVWUxOGhaYl…
Personalis (PSNL) Secures UKCA Marking for NeXT Personal Dx Test - GuruFocus
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxNU0VseVM5MmwtQlFhN0hzc0xQM045N05GbEdlWEktWGt2b3VfdnN3cFRfaTVZSlNoT2VMb1hadGFKbXg1RHhUbFlJU1dCUlYtMXlWZ1FuY0RQNk85SHZxSnE5cW01ZTB4dnBkTjhuQW1SS0FvQ214RnVTcDYtTHNwOFpYX05PR0dXZXFPN2…
PSNL Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE1hejhpeXpFbVN2YWo1aDRLUWh2V0tpQXpybDF6QlFIdC03UmdmajZjeGt0aXdfMjhfaV8xZHR0Nzg2QzRjd3JWVXRpUGRON0JfTEhucEdTbkI4bmhOaWYtYktpeXhjS05iVzc2aDRCZTc5UXhqeW54VEtR?oc=5" target="_blank">PSN…
PSNL — Frequently Asked Questions
What is the current share price of Personalis, Inc. (PSNL)?
As of 2026-07-14 21:23 PDT, Personalis, Inc. (PSNL) trades at $15.03 on NasdaqGM. Its 52-week range is $4.40 to $15.04.
What is the market capitalisation of PSNL?
Personalis, Inc. (PSNL) has a market capitalisation of $1.57B on NasdaqGM.
What is the P/E ratio of PSNL?
PSNL trades at a trailing price-to-earnings (P/E) ratio of -14.74. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 3.94.
What is the return on equity (ROE) of PSNL?
PSNL has a return on equity (ROE) of -41.35%. Its return on capital employed (ROCE) is -27.52%.
Is PSNL a good stock to buy?
This page provides a data-driven analysis of Personalis, Inc. (PSNL), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.